Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1997 Jan;35(1):187–192. doi: 10.1128/jcm.35.1.187-192.1997

Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method.

A Hawkins 1, F Davidson 1, P Simmonds 1
PMCID: PMC229536  PMID: 8968905

Abstract

The accuracy of different methods for the quantitation of hepatitis C virus in plasma was measured with samples from individuals infected with different genotypes and by using RNA transcripts of predetermined concentrations. Highly reproducible results were observed upon repeat testing of samples by both the original version of the Chiron branched-DNA (bDNA) assay (Quantiplex RNA assay; bDNA-1) and the currently available version (Quantiplex HCV RNA 2.0 assay; bDNA-2). A greater variability was observed in the Roche Monitor assay (correlation coefficient of 0.537, compared with 0.942 and 0.964 for the bDNA-1 and bDNA-2 assays, respectively). Significant differences in the efficiency of detection of genotypes 1, 2, and 3 were observed for the bDNA-1 and Roche Monitor assays, whereas the bDNA-2 assay and nested PCR at limiting dilution were able to quantify genotypes with equal sensitivity. By quantifying RNA transcripts of different genotypes, the sensitivities of the Roche Monitor assay for sequences of the type 2 and type 3 transcripts were estimated to be 11 and 8% of those achieved for genotype 1. When correction factors based upon these results and those from quantitation of circulating viral RNA sequences in samples from blood donors were used, the genotype-specific differences in virus load in samples from blood donors were no longer observed, consistent with previous studies with corrected values from the bDNA-1 assay. These results suggest that many of the previous studies evaluating the effect of genotype and virus load on the response to interferon using methods such as the Roche Monitor assay and other competitive PCR methods require reinterpretation. Differences in efficiency of quantitation should be taken into account in future investigations of the relationship between genotype and virus load.

Full Text

The Full Text of this article is available as a PDF (177.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berger A., von Depka Prondzinski M., Doerr H. W., Rabenau H., Weber B. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection. J Med Virol. 1996 Apr;48(4):339–343. doi: 10.1002/(SICI)1096-9071(199604)48:4<339::AID-JMV7>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]
  2. Chan C. Y., Lee S. D., Hwang S. J., Lu R. H., Lu C. L., Lo K. J. Quantitative branched DNA assay and genotyping for hepatitis C virus RNA in Chinese patients with acute and chronic hepatitis C. J Infect Dis. 1995 Feb;171(2):443–446. doi: 10.1093/infdis/171.2.443. [DOI] [PubMed] [Google Scholar]
  3. Chan S. W., McOmish F., Holmes E. C., Dow B., Peutherer J. F., Follett E., Yap P. L., Simmonds P. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol. 1992 May;73(Pt 5):1131–1141. doi: 10.1099/0022-1317-73-5-1131. [DOI] [PubMed] [Google Scholar]
  4. Collins M. L., Zayati C., Detmer J. J., Daly B., Kolberg J. A., Cha T. A., Irvine B. D., Tucker J., Urdea M. S. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal Biochem. 1995 Mar 20;226(1):120–129. doi: 10.1006/abio.1995.1199. [DOI] [PubMed] [Google Scholar]
  5. Daly J. A., Ertingshausen G. Direct method for determining inorganic phosphate in serum with the "CentrifiChem". Clin Chem. 1972 Mar;18(3):263–265. [PubMed] [Google Scholar]
  6. Davidson F., Simmonds P., Ferguson J. C., Jarvis L. M., Dow B. C., Follett E. A., Seed C. R., Krusius T., Lin C., Medgyesi G. A. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region. J Gen Virol. 1995 May;76(Pt 5):1197–1204. doi: 10.1099/0022-1317-76-5-1197. [DOI] [PubMed] [Google Scholar]
  7. Davis G. L. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol. 1994 Jul;21(1):1–3. doi: 10.1016/s0168-8278(94)80128-2. [DOI] [PubMed] [Google Scholar]
  8. Detmer J., Lagier R., Flynn J., Zayati C., Kolberg J., Collins M., Urdea M., Sánchez-Pescador R. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol. 1996 Apr;34(4):901–907. doi: 10.1128/jcm.34.4.901-907.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hayashi J., Kishihara Y., Yoshimura E., Tani Y., Yamaji K., Ikematsu H., Ishiko H., Kashiwagi S. Relationship of genotype to level of hepatitis C viraemia determined by competitive polymerase chain reaction. J Infect. 1995 May;30(3):235–239. doi: 10.1016/s0163-4453(95)90785-8. [DOI] [PubMed] [Google Scholar]
  10. Jarvis L. M., Ludlam C. A., Ellender J. A., Nemes L., Field S. P., Song E., Chuansumrit A., Preston F. E., Simmonds P. Investigation of the relative infectivity and pathogenicity of different hepatitis C virus genotypes in hemophiliacs. Blood. 1996 Apr 1;87(7):3007–3011. [PubMed] [Google Scholar]
  11. Lau J. Y., Davis G. L., Kniffen J., Qian K. P., Urdea M. S., Chan C. S., Mizokami M., Neuwald P. D., Wilber J. C. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 1993 Jun 12;341(8859):1501–1504. doi: 10.1016/0140-6736(93)90635-t. [DOI] [PubMed] [Google Scholar]
  12. Lau J. Y., Davis G. L., Prescott L. E., Maertens G., Lindsay K. L., Qian K., Mizokami M., Simmonds P. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med. 1996 May 15;124(10):868–876. doi: 10.7326/0003-4819-124-10-199605150-00002. [DOI] [PubMed] [Google Scholar]
  13. Lau J. Y., Simmonds P., Urdea M. S. Implications of variations of "conserved" regions of hepatitis C virus genome. Lancet. 1995 Aug 12;346(8972):425–426. doi: 10.1016/s0140-6736(95)92786-7. [DOI] [PubMed] [Google Scholar]
  14. Mahaney K., Tedeschi V., Maertens G., Di Bisceglie A. M., Vergalla J., Hoofnagle J. H., Sallie R. Genotypic analysis of hepatitis C virus in American patients. Hepatology. 1994 Dec;20(6):1405–1411. doi: 10.1002/hep.1840200605. [DOI] [PubMed] [Google Scholar]
  15. Martinot-Peignoux M., Marcellin P., Pouteau M., Castelnau C., Boyer N., Poliquin M., Degott C., Descombes I., Le Breton V., Milotova V. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 1995 Oct;22(4 Pt 1):1050–1056. [PubMed] [Google Scholar]
  16. Matsumoto A., Tanaka E., Suzuki T., Ogata H., Kiyosawa K. Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C. Dig Dis Sci. 1994 Jun;39(6):1273–1280. doi: 10.1007/BF02093793. [DOI] [PubMed] [Google Scholar]
  17. McOmish F., Chan S. W., Dow B. C., Gillon J., Frame W. D., Crawford R. J., Yap P. L., Follett E. A., Simmonds P. Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities. Transfusion. 1993 Jan;33(1):7–13. doi: 10.1046/j.1537-2995.1993.33193142314.x. [DOI] [PubMed] [Google Scholar]
  18. Mita E., Hayashi N., Hagiwara H., Ueda K., Kanazawa Y., Kasahara A., Fusamoto H., Kamada T. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci. 1994 May;39(5):977–982. doi: 10.1007/BF02087547. [DOI] [PubMed] [Google Scholar]
  19. Mizokami M., Orito E., Gibo Y., Suzuki K., Ohba K., Ohno T., Lau J. Y. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C. Liver. 1996 Feb;16(1):23–27. doi: 10.1111/j.1600-0676.1996.tb00699.x. [DOI] [PubMed] [Google Scholar]
  20. Nousbaum J. B., Pol S., Nalpas B., Landais P., Berthelot P., Bréchot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med. 1995 Feb 1;122(3):161–168. doi: 10.7326/0003-4819-122-3-199502010-00001. [DOI] [PubMed] [Google Scholar]
  21. Orito E., Mizokami M., Nakano T., Terashima H., Nojiri O., Sakakibara K., Mizuno M., Ogino M., Nakamura M., Matsumoto Y. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C. J Med Virol. 1994 Dec;44(4):410–414. doi: 10.1002/jmv.1890440418. [DOI] [PubMed] [Google Scholar]
  22. Simmonds P., Balfe P., Peutherer J. F., Ludlam C. A., Bishop J. O., Brown A. J. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol. 1990 Feb;64(2):864–872. doi: 10.1128/jvi.64.2.864-872.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Simmonds P., Zhang L. Q., Watson H. G., Rebus S., Ferguson E. D., Balfe P., Leadbetter G. H., Yap P. L., Peutherer J. F., Ludlam C. A. Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users. Lancet. 1990 Dec 15;336(8729):1469–1472. doi: 10.1016/0140-6736(90)93179-s. [DOI] [PubMed] [Google Scholar]
  24. Smith D. B., Davidson F., Yap P., Brown H., Kolberg J., Detmer J., Urdea M., Simmonds P., International HCV Collaborati Levels of hepatitis C virus in blood donors infected with different viral genotypes. International HCV Collaborative Study Group. J Infect Dis. 1996 Mar;173(3):727–730. doi: 10.1093/infdis/173.3.727. [DOI] [PubMed] [Google Scholar]
  25. Smith D. B., Mellor J., Jarvis L. M., Davidson F., Kolberg J., Urdea M., Yap P. L., Simmonds P. Variation of the hepatitis C virus 5' non-coding region: implications for secondary structure, virus detection and typing. The International HCV Collaborative Study Group. J Gen Virol. 1995 Jul;76(Pt 7):1749–1761. doi: 10.1099/0022-1317-76-7-1749. [DOI] [PubMed] [Google Scholar]
  26. Warshaw M. M., Tinoco I., Jr Optical properties of sixteen dinucleoside phosphates. J Mol Biol. 1966 Sep;20(1):29–38. doi: 10.1016/0022-2836(66)90115-x. [DOI] [PubMed] [Google Scholar]
  27. Yamada G., Takatani M., Kishi F., Takahashi M., Doi T., Tsuji T., Shin S., Tanno M., Urdea M. S., Kolberg J. A. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology. 1995 Nov;22(5):1351–1354. [PubMed] [Google Scholar]
  28. Young K. K., Resnick R. M., Myers T. W. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol. 1993 Apr;31(4):882–886. doi: 10.1128/jcm.31.4.882-886.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Zhang L. Q., Simmonds P., Ludlam C. A., Brown A. J. Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates. AIDS. 1991 Jun;5(6):675–681. doi: 10.1097/00002030-199106000-00006. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES